UNSPSC 51434817: Sagandipine

This classification denotes a calcium channel blocker with the molecular formula C27H31FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 20O65J0B72, chemically known as methyl (5-piperidinomethyl)furfuryl 4-(o-fluorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate. but generally known as sagandipine, which bears US NIH Compound Identifier 3058740. European Medicines Agency schedules Sagandipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10414MIG.

UNSPSC 51434817 Sagandipine is a Commodity code covering pharmaceutical active pharmaceutical ingredients and finished dosage forms procured directly by state and local health agencies, emergency services, and multistate cooperative purchasing groups. State and local governments buy finished medications under this code—typically injectable formulations for emergency medical services, hospital systems, and health benefit programs—rather than raw chemical compounds. The issuing bodies soliciting under the code span city fire and rescue departments, state health commissions, and multistate cooperative purchasing alliances coordinating procurement across multiple states and localities. Recent solicitations show demand for both direct pharmaceutical supply contracts and broader pharmacy benefit program infrastructure, with vendors expected to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and OSHA safety documentation standards.

Recent activity appears in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with sealed bids due April 8, 2026, and an estimated contract value of $40,000.00 under a Small Local Business Enterprise (SLBE) sheltered market with a 5 percent bid discount. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) in March 2026 to explore Direct-to-Manufacturer Prescriptions capabilities for its Therapeutic Pharmacy Initiative, seeking vendor experience with direct contracting outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration, through the Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026, and a two-year term with optional extensions.